

## Review

The ALPORA Innovation Europa Fund was unable to escape the ongoing correction on the global equity markets in August, but was able to defend a good part of its outperformance on an annual basis against the benchmark index MSCI Europe TRN.

The Spanish company Faes Farma S.A. develops, produces and distributes pharmaceutical products primarily in Spain and Portugal, and with an increasing share also in Japan, South America and Africa. Their prescription medications fight cardiovascular, respiratory, and central nervous system disorders as well as musculoskeletal and osteoporosis-related diseases. The FAES 2020 project, launched in 2015, defined the goal of successfully developing 20 new, highly effective drugs within five years. The research centre has been expanded. It is divided into three areas (active ingredients, pharmaceutical technologies and clinical research) and employs around 70 highly qualified staff. In addition to initial successes with Bilastin in Japan (treatment of hay fever and urticaria), Hydroferol (vitamin D deficiency) and Claversal in Spain (chronic inflammatory bowel disease), a further 15 products in development are being brought to market.

With its strategy Faes Farma is actively responding to the trend towards continuously improving health care.

## ALPORA Selection Process

Alpora has developed a completely new method, which identifies innovative companies according to branches, regions or market-capitalisation based on key business ratios, and rates them based on their individual innovation efficiency. The selection is made in a three-stage method through a large number of measurable innovation indicators. This unique analytical approach (ICA – Innovation Capability Analytics) is based on scientific research and comprises purely quantitative criteria. The classification forms the basis for the portfolio definition.

## AMG Selection Process

AMG selects the most robust 30 companies according to fundamental criteria from out of Europe's top innovators determined by Alpora. The focus here is placed on the stability of the balance sheet, tradability as well as the development of profitability. The company's financial strength should enable it to achieve its existing potential. Valuation ratios are secondary for this selection, so that also companies in young growth stages can be taken into consideration in the portfolio composition.

## Facts

Domicile of Fund:	Switzerland
Fund Management Company:	LLB Swiss Investment Ltd, Zurich
Custodian Bank:	Bank J. Safra Sarasin Ltd, Basel
Investment Manager:	AMG Fondsverwaltung AG, Zug
Reference currency:	EUR
Launch date:	01.10.2014 (EUR A + CHF-hedged) 09.07.2019 (EUR B)
ISIN:	CH0248877885 (EUR A) CH0436491234 (EUR B) CH0302271066 (CHF-hedged)
Distributions:	none, dividend reinvested
Subscription / Redemption:	Daily / no fees
Performance Fee:	None
Management Fee:	1.0% (EUR A + CHF-hedged) 1.5% (EUR B)
TER (31.12.2018):	1.26% (EUR A + CHF-hedged)
Tax transparency:	Switzerland, Austria
Tax Status Germany:	Equity Fund within the meaning of the German investment tax law (InvStG) with part. release
Registered for public distribution:	Switzerland, Germany

## Distribution

AMG Fondsverwaltung Ltd. is responsible for the Distribution of the ALPORA Innovation Europe Fund:

**AMG Fondsverwaltung AG**  
Bahnhofstr. 29  
6300 Zug  
Phone +41 41 726 71 71  
www.amg.ch  
fonds@amg.ch


## Key Figures

<b>Net Asset Value Tranche EUR A:</b>	<b>EUR 1'803.52</b>
Number of Shares Issued:	43'804
<b>Net Asset Value Tranche EUR B:</b>	<b>EUR 1'802.28</b>
Number of Shares Issued:	1'221
<b>Net Asset Value Tranche CHF-hedged:</b>	<b>CHF 1'951.98</b>
Number of Shares Issued:	17'467
Total Net Asset Value:	EUR 112.5 Mio.


## Performance - Tranche EUR A

	1 Month	3 Months	12 Months	3 Years*	since Inception*	
Fund	-4.3%	-0.9%	-3.1%	9.1%	12.8%	
MSCI Europe TRN	-1.4%	3.2%	2.4%	6.3%	4.9%	
					*p.a.	
	2019	2018	2017	2016	2015	since Inception
Fund	20.9%	-14.3%	29.7%	-0.5%	28.0%	81.0%
MSCI Europe TRN	14.9%	-10.6%	10.2%	2.6%	8.2%	26.6%

## Performance since issue



## Monthly Performance vs. MSCI Europe TR Net



## Risk Ratios (rolling over the last 3 Years)

Volatility (p.a.):	13.3%
Sharpe Ratio (-0.41% Risk Free Rate):	0.73
Beta (vs. MSCI Europe TR Net):	0.95

## Breakdown by Sectors and Currencies

Technology	27.1%	EUR	41.3%
Health Care	21.5%	CHF	26.7%
Industrials	14.6%	GBP	18.0%
Consumer Staples	12.5%	NOK	7.1%
Energy	9.2%	SEK	6.1%
Basic Materials	8.1%		
Consumer Disc.	2.8%		
Communication	2.6%		
Cash	1.6%		

## Breakdown by Countries

Switzerland	25.7%	Sweden	6.1%
United Kingdom	18.0%	Belgium	4.6%
Germany	13.1%	Spain	4.6%
Norway	7.1%	France	2.9%
Netherlands	7.1%	Others	2.1%
Italy	7.0%	Cash	1.6%